

Jan 21, 2026

AD Biomarker

DOI

<https://dx.doi.org/10.17504/protocols.io.bp2l6dop5vqe/v1>

Abhay Moghekar¹

¹Johns Hopkins University

Abhay Moghekar: On behalf of the Precision Aging Network



Joel Parker

University of Arizona

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.bp2l6dop5vqe/v1>

Protocol Citation: Abhay Moghekar 2026. AD Biomarker . protocols.io

<https://dx.doi.org/10.17504/protocols.io.bp2l6dop5vqe/v1>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working



Created: March 11, 2025

Last Modified: January 21, 2026

Protocol Integer ID: 124196

Keywords: quantitative plasma biomarker measurement, biomarker, key biomarker, neurodegenerative disease, including alzheimer, simoa neuro, general brain health panel, advanced digital immunoassay, abeta1

Funders Acknowledgements:

Precision Aging Network

Grant ID: U19AG065169

Abstract

The general brain health panel provides quantitative plasma biomarker measurements commonly associated with neurodegenerative diseases, including Alzheimer's. These biomarkers are quantified using two advanced digital immunoassays. The Simoa Neuro 4-Plex E assay measures concentrations of four key biomarkers: Abeta1-40, Abeta 1-42, GFAP, and NF-light. Additionally, the Simoa Human pTau-181 Advantage assay specifically quantifies pTau-181.

SOP

1



Johns Hopkins Testing SOPV1.pdf

Data

2

Description:

The general brain health panel provides quantitative plasma biomarker measurements commonly

associated with neurodegenerative diseases, including Alzheimer's. These biomarkers are quantified using two advanced digital immunoassays. The Simoa Neuro 4-Plex E assay measures concentrations of four key biomarkers: Abeta 1-40, Abeta 1-42, GFAP, and NF-light. Additionally, the Simoa Human pTau-181 Advantage assay specifically quantifies pTau-181.

Data: Duplicate concentrations of each biomarker, measured in picograms per milliliter (pg/mL), are measured for each sample. The mean of the two replicate measurements for each biomarker are reported in the {biomarkername} columns. The {biomarkername}_SD_5 columns are the calculated 5*SDs from the mean for each biomarker based on the mean over all PAN participants.